Physician profile
Jonathan Jonisch
NPI 1467613216
$725,716.86
in general payments reported to CMS, 2019-2025
22 companies · $130K in 2025
The $130K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63K · 2020: $38K · 2021: $27K · 2022: $101K · 2023: $188K · 2024: $179K · 2025: $130K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $297K · Consulting Fee: $105K · Honoraria: $33K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $27K · Travel and Lodging: $22K · Food and Beverage: $14K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $296,645.17 |
| Consulting Fee | $104,889.00 |
| Honoraria | $32,612.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $26,650.00 |
| Travel and Lodging | $21,991.51 |
| Food and Beverage | $14,016.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $299,688.72 | 2019-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $245,167.14 | 2021-2025 | Syfovre, Syfovre |
| Genentech USA, INC. | $104,918.99 | 2019-2025 | Vabysmo, Lucentis |
| Novartis Pharmaceuticals Corporation | $52,249.37 | 2019-2021 | |
| Coherus Oncology, INC. | $7,935.81 | 2023-2024 | |
| Harrow Eye, LLC | $5,803.43 | 2025 | Triesence, Iheezo |
| Genentech, INC. | $4,798.77 | 2019-2023 | Susvimo |
| Regeneron Pharmaceuticals, INC. | $3,407.61 | 2022-2024 | Eylea Hd |
| Astellas Pharma US INC | $607.02 | 2023-2025 | Izervay |
| Alcon Vision LLC | $227.77 | 2022-2024 | Clareon |
| Cardinal Health 110 LLC | $150.00 | 2024 | |
| Abbvie INC. | $148.91 | 2022-2024 | |
| Tarsus Pharmaceuticals, INC. | $123.83 | 2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $119.32 | 2019 | |
| Allergan, INC. | $83.46 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $71.46 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $71.29 | 2021 | |
| Alimera Sciences, INC. | $70.07 | 2021-2022 | |
| Sandoz INC. | $33.03 | 2024 | Cimerli |
| Bausch & Lomb Americas INC. | $24.07 | 2022 | |
| Biogen, INC. | $16.79 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Jonisch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.